These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 18818521)

  • 41. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of the p53-mdm2 and p53-MDMX interfaces.
    Böttger V; Böttger A; Garcia-Echeverria C; Ramos YF; van der Eb AJ; Jochemsen AG; Lane DP
    Oncogene; 1999 Jan; 18(1):189-99. PubMed ID: 9926934
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.
    Jones SN; Sands AT; Hancock AR; Vogel H; Donehower LA; Linke SP; Wahl GM; Bradley A
    Proc Natl Acad Sci U S A; 1996 Nov; 93(24):14106-11. PubMed ID: 8943068
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans.
    Linke K; Mace PD; Smith CA; Vaux DL; Silke J; Day CL
    Cell Death Differ; 2008 May; 15(5):841-8. PubMed ID: 18219319
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Fusion Protein of the p53 Transaction Domain and the p53-Binding Domain of the Oncoprotein MdmX as an Efficient System for High-Throughput Screening of MdmX Inhibitors.
    Chen R; Zhou J; Qin L; Chen Y; Huang Y; Liu H; Su Z
    Biochemistry; 2017 Jun; 56(25):3273-3282. PubMed ID: 28581721
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
    Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
    EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of Mdm2 and Mdmx in DNA repair.
    Eischen CM
    J Mol Cell Biol; 2017 Feb; 9(1):69-73. PubMed ID: 27932484
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
    Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
    Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel simplified yeast-based assays of regulators of p53-MDMX interaction and p53 transcriptional activity.
    Leão M; Gomes S; Soares J; Bessa C; Maciel C; Ciribilli Y; Pereira C; Inga A; Saraiva L
    FEBS J; 2013 Dec; 280(24):6498-507. PubMed ID: 24119020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    Valianatos G; Valcikova B; Growkova K; Verlande A; Mlcochova J; Radova L; Stetkova M; Vyhnakova M; Slaby O; Uldrijan S
    PLoS One; 2017; 12(10):e0185801. PubMed ID: 28973015
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Roles of MDM2 and MDMX in Cancer.
    Karni-Schmidt O; Lokshin M; Prives C
    Annu Rev Pathol; 2016 May; 11():617-44. PubMed ID: 27022975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
    Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
    Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery.
    Popowicz GM; Czarna A; Wolf S; Wang K; Wang W; Dömling A; Holak TA
    Cell Cycle; 2010 Mar; 9(6):1104-11. PubMed ID: 20237429
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mdmx: a p53 activator?
    Jochemsen AG
    Cell Cycle; 2012 Mar; 11(5):843. PubMed ID: 22356751
    [No Abstract]   [Full Text] [Related]  

  • 56. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Is MDMX the better target?
    Kon N; Gu W
    Aging (Albany NY); 2018 Jun; 10(6):1184-1185. PubMed ID: 29905531
    [No Abstract]   [Full Text] [Related]  

  • 58. p53 Phosphomimetics Preserve Transient Secondary Structure but Reduce Binding to Mdm2 and MdmX.
    Levy R; Gregory E; Borcherds W; Daughdrill G
    Biomolecules; 2019 Mar; 9(3):. PubMed ID: 30832340
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MdmX inhibits ARF mediated Mdm2 sumoylation.
    Ghosh M; Weghorst K; Berberich SJ
    Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of MdmX on Mdm2-mediated downregulation of pRB.
    Uchida C; Miwa S; Isobe T; Kitagawa K; Hattori T; Oda T; Yasuda H; Kitagawa M
    FEBS Lett; 2006 Mar; 580(7):1753-8. PubMed ID: 16510145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.